Hairy cell leukemia expresses programmed death-1
Open Access
- 5 November 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 10 (11), 1-4
- https://doi.org/10.1038/s41408-020-00384-1
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximabExpert Review of Anticancer Therapy, 2015
- Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic LeukemiaActa Haematologica, 2015
- The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapyEmerging Therapeutic Targets, 2014
- PD‐1 as a potential target in cancer therapyCancer Medicine, 2013
- Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic LeukemiaPLOS ONE, 2012
- Diagnosis of hairy cell leukemia by flow cytometryLeukemia & Lymphoma, 2011
- Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemiaHuman Pathology, 2008
- Immunophenotyping and Differential Diagnosis of Hairy Cell LeukemiaHematology/Oncology Clinics of North America, 2006
- Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInternational Immunology, 1996
- The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes.1994